Credit Suisse analyst Lorenzo Biasio upgraded Illumina (ILMN – Research Report) to Hold yesterday and set a price target of $340.00. The company’s shares closed last Wednesday at $330.19, close to its 52-week low of $306.66.
According to TipRanks.com, Biasio is a 4-star analyst with an average return of 7.5% and a 61.1% success rate. Biasio covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, Merck & Company, and Thermo Fisher.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Illumina with a $417.55 average price target, representing a 25.3% upside. In a report issued on February 15, UBS also maintained a Hold rating on the stock with a $350.00 price target.
The company has a one-year high of $526.00 and a one-year low of $306.66. Currently, Illumina has an average volume of 1.04M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incorporated in 1998, Illumina, Inc. is a California-based company which develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Its products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The company’s products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting.
Read More on ILMN:
- JonesTrading Thinks Surface Oncology’s Stock is Going to Recover
- 2 “Strong Buy” Stocks Flashing Signs of Strong Insider Buying
- Alibaba: The Long-Term Opportunity Remains, Says Top Analyst
- RBC Capital Maintains a Hold Rating on Stellantis (STLA)
- Bitcoin: Economies of Scope Are the Way Forward for the BTC Mining Industry